Alzheimer’s drug trials target older Californians. Do they understand what they’re signing up for?
Los Angeles Times: Peter Whitehouse, professor at the College of Arts and Sciences, said drug trial investigators can “earn phenomenal amounts” for the patients they recruit. “There’s a bias for them to want to get people into these studies,” he said, noting that in some cases, he has found, “they overpromise the likely results of these trials and create false hope.”